First Command Advisory Services’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$39.5K Sell
313
-27
-8% -$3.56K ﹤0.01% 500
2026
Q1
$47.4K Buy
340
+229
+206% +$32.1K ﹤0.01% 361
2025
Q4
$13.6K Buy
111
+92
+484% +$11.2K ﹤0.01% 448
2025
Q3
$2.11K Hold
19
﹤0.01% 534
2025
Q2
$2.11K Sell
19
-28
-60% -$2.98K ﹤0.01% 496
2025
Q1
$5.27K Buy
47
+21
+81% +$2.17K ﹤0.01% 404
2024
Q4
$2.4K Hold
26
﹤0.01% 413
2024
Q3
$2.18K Hold
26
﹤0.01% 417
2024
Q2
$1.78K Sell
26
-10
-28% -$667 ﹤0.01% 444
2024
Q1
$2.64K Buy
+36
New +$2.77K ﹤0.01% 433
2021
Q4
Sell
-28
Closed -$2K 107
2021
Q3
$2K Buy
+28
New +$1.97K ﹤0.01% 34
2020
Q4
Sell
-75
Closed -$5K 54
2020
Q3
$5K Buy
+75
New +$5.2K ﹤0.01% 33

Other funds holding GILD

First Command Advisory Services's GILD Position: Q2 2026 in Review

First Command Advisory Services reduced its Gilead Sciences (GILD) stake by 7.9% in Q2 2026, selling an estimated $3.56K and leaving 313 shares worth $39.5K. The position accounts for ﹤0.01% of the portfolio, ranked #500.

First Command Advisory Services first reported a position in GILD in Q3 2020 and has held it in 12 quarters since. The position peaked at $47.4K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • First Command Advisory Services held 313 shares of Gilead Sciences worth $39.5K as of Q2 2026.
  • First Command Advisory Services sold 27 Gilead Sciences shares in Q2 2026, an estimated $3.56K.
  • Gilead Sciences made up ﹤0.01% of First Command Advisory Services's portfolio in Q2 2026, its #500 holding.
  • First Command Advisory Services first reported a position in Gilead Sciences in Q3 2020 and has held it in 12 quarters since.
  • First Command Advisory Services's Gilead Sciences position peaked at $47.4K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on First Command Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.